clinical trial · NCT07156149
Fabhalta Capsules Specified Drug-use Survey
C3 Glomerulopathy
brief summary
The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.
started
Sep 17, 2025
primary completion
Jun 30, 2028
completion
Jun 30, 2028
last updated
Apr 13, 2026
official title
Fabhalta Capsules Specified Drug-use Survey(C3 Glomerulopathy, CLNP023B11401)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol